The current status of hepatitis C

International Journal of Artificial Organs

Volumn 24, Issue 12, 2001, Pages 838-842

  Lin, R K ^a   Saab, S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURRENT STATUS; HEPATITIS C;

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; INTERFERON; MACROGOL; MACROGOL PLUS ALPHA2A INTERFERON; NUCLEOSIDE ANALOG; RIBAVIRIN; UNCLASSIFIED DRUG;

ALOPECIA; ANTIBODY DETECTION; ARTHRALGIA; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; EDITORIAL; FLU LIKE SYNDROME; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER BIOPSY; MYALGIA; NAUSEA; NONHUMAN; SEROLOGY; SEROPREVALENCE; THYROIDITIS; VIROLOGY; VIRUS TRANSMISSION;

EID: 0035715043     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880102401208     Document Type: Editorial

References (39)

1. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors
2. Transfusion-associated hepatitis not due to viral hepatitis type A or B
3. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
4. Variability of hepatitis C virus
5. The role of immune responses in the pathogenesis of hepatitis C virus infection
6. A population based serologic study of hepatitis C virus infection in the United States
7. Estimating future hepatitis C morbidity, mortality, and costs in the United States
8. Epidemiology of hepatitis C
9. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
10. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention
11. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
12. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
13. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis
14. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention
15. Epidemiology of hepatitis C in the west
16. Risk factors for acute non-A, non-B hepatitis and their relationship to antibodies for hepatitis C virus: A case-control study
17. Hepatitis C
18. Community acquired viral hepatitis B and C in the United States
19. Clinical and histological aspects of chronic HCV infection and cirrhosis
20. Hepatitis C and non-Hodgkin's lymphomas
21. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease
22. Hepatitis C: The clinical spectrum of disease
23. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: Clinical and histological outcome
24. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population
25. Antibody response to core, envelope and nonstructural hepatitis C virus antigen: Comparison of immunocompetent and immunosuppressed patients
26. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications
27. Measuring hepatitis C viremia in clinical samples: Can we trust the assays?
28. Interferon in viral hepatitis: Role in pathogenesis and treatment
29. Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials
30. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis
31. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
32. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
33. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
34. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis
35. Peginterferon alfa-2a in patients with chronic hepatitis C
36. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 weeks treatment analysis of a multicenter, multinational phase III randomized controlled trial
37. International Consensus Conference on Hepatitis. Consensus statement
38. Statement: Management of hepatitis C
39. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for first line treatment in patients with chronic hepatitis C?